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Abstract
Background: 3-Hydroxy-3-Methylglutaric aciduria (3HMG, McKusick: 246450) is an autosomal
recessive branched chain organic aciduria caused by deficiency of the enzyme 3-Hydroxy-3-
Methylglutaryl CoA lyase (HL, HMGCL, EC 4.1.3.4). HL is encoded by HMGCL gene and many
mutations have been reported. 3HMG is commonly observed in Saudi Arabia.
Methods: We utilized Whole Genome Amplification (WGA), PCR and direct sequencing to
identify mutations underlying 3HMG in the Saudi population. Two patients from two unrelated
families and thirty-four 3HMG positive dried blood spots (DBS) were included.
Results: We detected the common missense mutation R41Q in 89% of the tested alleles (64
alleles). 2 alleles carried the frame shift mutation F305fs (-2) and the last two alleles had a novel
splice site donor IVS6+1G>A mutation which was confirmed by its absence in more than 100
chromosomes from the normal population. All mutations were present in a homozygous state,
reflecting extensive consanguinity. The high frequency of R41Q is consistent with a founder effect.
Together the three mutations described account for >94% of the pathogenic mutations underlying
3HMG in Saudi Arabia.
Conclusion: Our study provides the most extensive genotype analysis on 3HMG patients from
Saudi Arabia. Our findings have direct implications on rapid molecular diagnosis, prenatal and pre-
implantation diagnosis and population based prevention programs directed towards 3HMG.
Background
3-Hydroxy-3-Methylglutaric aciduria (3HMG, McKusick
246450) is an autosomal recessive branched chain
organic aciduria caused by deficiency of the enzyme 3-
Hydroxy-3-Methylglutaryl CoA lyase (HL, HMGCL, EC
4.1.3.4). This mitochondrial enzyme catalyzes the last
step of both leucine degradation and ketogenesis[1].
Patients present in the neonatal or infantile period with
severe hypoketotic hypoglycemia, metabolic acidosis,
hyperammonemia, vomiting and hypotonia [2].
Untreated, this may progress rapidly to coma and death or
may result in permanent neurological damage. With treat-
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ment, many patients do well although recurrent meta-
bolic decompensation continues to occur especially with
prolonged fasting and inter-current infections. Although a
rare disease in Europe and Japan, it is reported to be com-
mon in Saudi Arabia and Portugal [3-5].
Rapid biochemical diagnosis by blood acylcarnitine anal-
ysis on DBS using tandem mass spectrometry reveals ele-
vation of 3-methylglutarylcarnitine and 3-
hydroxyisovalerylcarnitine [6]. Urine analysis by gas chro-
matography mass spectrometry reveals the presence of 3-
hydroxy-3-methylglutaric, 3-methylglutaconic and 3-
hydroxyisovaleric acids [7,8]. HL can also be measured in
various tissues including lymphocytes and fibroblasts
[9,10].
The human HMGCL cDNA[11] and gene were cloned and
localized to chromosome 1p36.11. It is composed of nine
exons [12,13]. Many mutations have been reported in var-
ious ethnic groups [4,5,11,13-17]. Two mutations "R41Q
and F305fs (-2)" have been previously identified in eight
patients from Saudi Arabia [18].
In this paper we report our findings on molecular analysis
of 72 alleles from Saudi Arabia.
Methods
Patients
Two patients from two apparently unrelated families were
included after informed consent was obtained. The diag-
nosis was made by the characteristic blood acylcarnitine
and urine organic acid profiles. A further thirty-four
3HMG positive DBS based on acylcarnitine analysis and
confirmed by urine organic acid analysis were obtained
from the National Laboratory for Newborn Screening. The
samples were referred to the laboratory from sick infants
where a metabolic disorder was suspected. No additional
clinical details are available on these patients. Waiver of
informed consent was provided by the Institutional
Review Board of the King Faisal Specialist Hospital and
Research Centre, on the basis of anonymization of all
study samples.
Sample collection and DNA extraction
DNA was prepared from peripheral blood from 3HMG
positive dried bloodspots. Briefly a sample 2 mm in diam-
eter was punched out from each dried blood spot and
placed in a 96-well plate. The 2 mm discs were re-hydrated
with 10 µl of phosphate-buffered saline (PBS) at room
temperature prior to DNA extraction and amplification.
Extraction and amplification were carried out as described
for the REPLI-g TM kit (Molecular Staging Inc., New
Haven, CT, USA) with minor modifications. Extractions
were assembled on ice by adding 10 µl of cell lysis solu-
tion (400 mM KOH, 10 mM EDTA at pH 8.0, and 50 mM
dithiothreitol), mixed briefly with the PBS-soaked discs
and incubated for 10 min. Then 10 µl of neutralization
solution (800 mM Tris-hydrochloride) was added and
mixed gently by pipetting. This lysate mixture (2 µl) was
then used as template per 10 µl of whole genome ampli-
fication (WGA) reaction.
Whole genome amplification (WGA)
WGA [19] was performed in a total volume of 10 µl.
Amplification reactions were assembled in 96-well plates
by mixing 2.5 µl 4× buffer, 5.4 µl ddH2O, 0.1 µl ø29 DNA
polymerase, and 2 µl of the lysate mixture. Reactions were
incubated at 30°C for 16 h and terminated by heating to
65°C for 3 min. The amplification reactions were diluted
50 fold in ddH2O (DNA concentration ~10 ng/µl) and
dilutions used in PCR amplification and direct sequenc-
ing.
PCR amplification of WGA DNA
For sequence analysis WGA generated DNA was amplified
by PCR using intronic primers designed to amplify the 9
coding exons of the HMGCL  gene (primer sequences
available on request). PCR was performed using the DNA
Engine PTC-200 (MJ Research; Watertown, MA, USA;[20])
in a final volume of 20 µl containing approximately 10 ng
of genomic DNA, 50 mM KCl, 10 mM Tris-HCl (pH 8.3),
1.5 mM MgCl2, 100 µM deoxyribonucleotide triphos-
phates (dNTPs), 1 unit of Qiagen (Valencia CA, USA)
HotStar Taq polymerase, and 50 ng of each primer. Ther-
mocycling consisted of an initial denaturation at 95°C for
15 min followed by 35 cycles of PCR. Each cycle of PCR
consisted of denaturation at 94°C for 60 s, annealing at
62–68°C for 60 s and extension at 72°C for 60 s. A final
extension step of 10 min at 72°C was added.
Mutation detection
Sequencing reactions were performed using an Amersham
ET Dye Terminator Cycle Sequencing Kit (Amersham Bio-
sciences; Piscataway, NJ, USA [21]) following the manu-
facturers instructions. Sequencing reactions were desalted
and unincorporated nucleotides removed using ethanol
precipitation and re-suspended in a formamide EDTA
solution for injection on a MegaBACE 1000 DNA Analysis
System (Molecular Dynamics; Sunnyvale, CA, USA).
Sequence analysis was performed using the SeqManII
module of the Lasergene (DNA Star Inc. WI, USA) soft-
ware package, then compared to the reference GenBank
sequence (accession no. AF376770). Numbering com-
menced with the A of the ATG initiation codon as +1.
Genotyping
Genotyping of the marker D1S2620 (<0.5 cM from
HMGCL) was performed using fluorescently labeled prim-
ers (5'-FAM-AAGAGTTGTCCAACCAAATTG-3' and 5'-
GAATCTGGGATGGGATGT-3') for PCR amplificationBMC Medical Genetics 2006, 7:86 http://www.biomedcentral.com/1471-2350/7/86
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(essentially as described above) of alleles which were
identified following capillary electrophoresis on a Mega-
bace 1000 and fragment size analysis using Genetic Pro-
filer software (Amersham, Sunnyvale, CA). Alleles were
assigned alphabetically following genotyping of patient
samples and over 100 chromosomes from the normal
population.
URLs
We used the Ensembl website [22] to obtain exon and
intron boundaries, the reference GenBank cDNA
sequence, and Primer3 to design appropriate primers
[23].
Results
Three pathogenic mutations were identified in 72 alleles
examined from 3HMG positive DBS. 89% of the alleles
(64) were positive for the missense R41Q (122G>A)
mutation. One patient was homozygous for the previ-
ously reported frame shift mutation F305fs(-2) and
another homozygous for a novel splice site donor
IVS6+1GA mutation (Figure 1). Demonstration of the
pathogenicity of this mutation was not possible as all
samples in this retrospective study were anonymized as a
condition for IRB approval. This mutation was confirmed
by its absence in more than100 chromosomes from the
normal population. No mutation was identified in four
remaining alleles. Together the three mutations account
for 95% of the pathogenic mutations underlying HL defi-
ciency in our Saudi Arabian patients.
All individuals that were homozygous for the R41Q muta-
tion had a B/B genotype at the D1S2620 microsatellite
marker on chromosome 1. The incidence of the B allele in
the normal population was 0.46, which is statistically sig-
nificant relative to the 100% incidence in patients with
3HMG deficiency who were homozygous for the R41Q
mutation (p = 0.002). This is consistent with R41Q being
a founder mutation in the Saudi Arabian population.
Discussion
In contrast to Europe and Japan, 3HMG is commonly seen
in Saudi Arabia [3]. We undertook the task of identifying
the underlying mutation in our patients for several rea-
sons. Whilst newborn screening programs are useful for
early detection and intervention to reduce morbidity and
mortality, they are based upon biochemical profiling
which is unable to reliably detect carrier status. Identifica-
tion of mutations underlying the majority of 3HMG cases
in the Saudi population provides opportunities for pre-
vention through socially accepted procedures such as
PGD, but more importantly provides the basis for carrier
detection and inductive pre-marital counselling which
has the potential to prevent this and other similar heredi-
tary diseases in future generations. The identification of a
single or limited number of founder mutations in the
population would also provide the basis upon which an
inductive or selective screening program could be con-
ducted. This would also depend on the representative
nature of the samples screened in this study. Given that
the samples tested are the total experience of our meta-
bolic screening laboratory over a 10 year period and that
it receives all cases of suspected inborn errors of metabo-
lism in Saudi Arabia, the sample can be considered to be
representative.
Our study confirms that the previously reported R41Q
mutation in Saudi patients is indeed the most common
Sequence analysis of PCR-amplified fragments of the HMGCL gene of patients and controls Figure 1
Sequence analysis of PCR-amplified fragments of the HMGCL gene of patients and controls. A: The arrow indicates a hetero-
zygous R41Q (122 G>A) mutation in a carrier of 3HMG; B: The position of the arrow indicates a homozygous F305fs (-2) (-
TT) mutation in an affected 3HMG patient and C: The arrow indicates a homozygous IVS6+1G>A mutation in an affected 
3HMG patient.BMC Medical Genetics 2006, 7:86 http://www.biomedcentral.com/1471-2350/7/86
Page 4 of 5
(page number not for citation purposes)
mutation. It accounts for 89% of the pathogenic 3HMG
alleles in Saudi Arabia. The high incidence of R41Q (89%)
suggests a common founder and is consistent with the
demographic observation that the majority of patients
come from a single ancient tribe in Saudi Arabia. This was
confirmed by genotype analysis at the D1S2620 microsat-
ellite marker on chromosome 1 (see Results). The major-
ity of the patients reported in the literature with R41Q
mutation are of Saudi origin [18]. A Czech patient [24]
and a Turkish patient homozygous for R41Q together
with an Italian patient heterozygous for this mutation
have also been identified [18]. Both Turkey and Italy were
subject to migration from the Arabian Peninsula during
the Arabic invasion. As observed with Carbonic Anhy-
drase II deficiency [25], the likely hood of R41Q migrating
from the Arabian Peninsula exists, however the presence
of this mutation in three different countries raises the
hypothesis that this mutation has arisen independently
more than once. More extensive haplotype analysis from
patients from these regions may be helpful in tracing the
origin of this mutation.
Among the 6 Saudi patients previously reported with this
mutation, clinical data is available on four [26]. In two,
symptoms started at 3 days of age and the other two at 2
and 6 months respectively. Of three patients included in
our study from whom clinical data is available, two had
onset of disease at 5 months and one at 3 days of age
respectively. Furthermore, we identified six more patients
homozygous for R41Q mutation in whom testing was
offered on clinical grounds. All patients presented
between 3–8 months of age following intercurrent illness.
Currently all nine patients are on a restricted leucine and
fat diet in addition to carnitine. They are followed at our
metabolic clinic and are doing well with normal growth
and development. The above data indicates that the R41Q
mutation can be associated with either neonatal or infan-
tile presentation. Furthermore, in contrast to previous
suggestion that 3HMG in Saudi Arabia is a neonatal-onset
organic acidemia [26], our data as shown above indicates
that infantile presentation is also quite common. Good
neurodevelopmental outcome is observed in the majority
of the patents provided appropriate medical attention is
given during episodes of crisis especially in the first few
years of life.
No clinical data is available on the other two mutations
identified in our study, however one Saudi patient
reported previously with F305fs (-2) mutation had a neo-
natal onset of the disease. Growth and development was
reported to be normal at 15 months of age [27]. It is inter-
esting to note that this mutation has not been identified
so far in any other ethnic group.
Conclusion
Our study provides the most extensive genotype analysis
on 3HMG patients from Saudi Arabia. Based on our
results, we recommend that all patients of Saudi ethnicity
diagnosed with 3HMG be tested for the above three muta-
tions. Patients negative for these mutations should be the
basis of further HMGCL  sequence analysis to identify
additional rare mutation(s) in the Saudi Population. Test-
ing for these three mutations should also be included in
any population based screening program for 3HMG in
Saudi Arabia.
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